Xilio Therapeutics (XLO) Notes Payables (2020 - 2023)

Xilio Therapeutics has disclosed Notes Payables across 3 years of filings, most recently posting $3.3 million for Q4 2023.

• Notes Payables for Q4 2023 came in at $3.3 million, down 50.28% year-over-year; the trailing twelve-month figure through Dec 2023 was $3.3 million (down 50.28% YoY), and the FY2023 annual result was $3.3 million, down 50.28% from the prior year.
• Notes Payables came in at $3.3 million for Q4 2023 at Xilio Therapeutics, down from $5.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $7.1 million in Q2 2023 to a low of $1.7 million in Q1 2022.
• The 3-year median for Notes Payables is $5.0 million (2023), against an average of $4.6 million.
• Peak annual rise in Notes Payables reached 299.94% in 2023, while the deepest fall reached 50.28% in 2023.
• Xilio Therapeutics' Notes Payables stood at $2.3 million in 2020, then jumped by 185.77% to $6.7 million in 2022, then sank by 50.28% to $3.3 million in 2023.
• The last three Notes Payables figures came in at $3.3 million (Q4 2023), $5.0 million (Q3 2023), and $7.1 million (Q2 2023), per Business Quant data.